NRXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
NRX Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$2.63+0.03 (+1.15%)
Close on Oct 19, 2026
- Market cap
- $99.02M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.55 (−17.30%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
NRX Pharmaceuticals, Inc. reported revenue of $3.39M for the twelve months to Jun 30, 2026.
Revenue
$3.39M
TTM Q2 2026
Operating income
-$19.90M
TTM Q2 2026
EPS, diluted
-$0.73
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $99.02M
- P/E ratio
- –
- Price to sales
- 29.17
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $3.39M
- Net income
- -$23.48M
- EPS, diluted
- -$0.73
- Book value per share
- -$0.00
- Diluted shares
- 38M
Nine years at a glance
Fiscal years 2017 to 2025 and trailing twelve months, USD
Revenue
$3.39M
Gross profit
$1.58M
Operating income
-$19.90M
Net income
-$23.48M
EPS, diluted
-$0.73
Free cash flow
–
Reported periodTrailing twelve months